Tocilizumab for the Treatment of Severe COVID-19 Pneumonia in Critically Ill Patients: Trendy or Tried-and-True?

This resource details an the usage of tocilizumab as a treatment for severe COVID-19.
This is SCCM curated COVID-19 microlearning content.

Faculty: Jessica A. Ward, Pharm.D.

This educational activity was funded in part by a cooperative agreement with the Centers for Disease Control and Prevention (grant number 1 NU50CK000566-01-00). The Centers for Disease Control and Prevention is an agency within the Department of Health and Human Services (HHS). Its contents do not necessarily represent the policy of CDC or HHS, and should not be considered an endorsement by the Federal Government.

Estimated Time: 05:20 min